Ascribing sell ratings to Lupin, Dr Reddy’s Laboratories, Zydus Lifesciences and Aurobindo Pharma, the brokerage said the US generic market has been declining and the pace could worsen.
UBS picks 2 pharma stocks that are likely to give 23-26% returns
